Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment

PITTSBURGH, Aug. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today
announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market
1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with
licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant
Pharmaceuticals International. The preparation is the first generic version of
Sanofi Aventis' BenzaClin(R) to be approved by the U.S. Food and Drug
Administration (FDA).

On Aug. 11, Dow received FDA approval for its Abbreviated New Drug Application
(ANDA) for Clindamycin 1% and Benzoyl Peroxide 5% Gel, a prescription-strength
topical antibiotic used to treat acne. According to IMS Health, BenzaClin had
total U.S. sales of approximately $221 million for the 12 months ending June
30.

Mylan Inc., which provides products to customers in more than 140 countries
and territories, ranks among the leading diversified generics and specialty
pharmaceutical companies in the world. The company maintains one of the
industry's broadest - and highest quality - product portfolios, supported by a
robust product pipeline; operates a controlling interest in the world's third
largest active pharmaceutical ingredient manufacturer; and runs a specialty
business focused on respiratory and allergy therapies. For more information,
please visit www.mylan.com.

SOURCE Mylan Inc.

Media, Michael Laffin, +1-724-514-1968, or Investors, Dan Crookshank,
+1-724-514-1813, both of Mylan Inc.